Table 3. Patients´ Characteristics.
| Diagnosis | %Blast Cells | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| No# | F/M | Age Yrs | FAB | WHO | WBC x109/L | PB | BM | Karyotype | Molecular Defects (Mutations) |
| 1* | F | 32 | M1 | AML with t(9;11) | 0.4 | 80% | 73% | 46,XX, t(9;11) | MLL1-AF9 |
| 2 | M | 61 | M5 | AML monoblastic | 35.1 | 33% | 72% | 46,XY, t(11;17) | MLL1-MSF |
| 3 | M | 65 | M5 | AML with t(9;11)/NPM1m | 94.8 | 6% | 90% | 47,XY, t(9;11),+8 | MLL1-AF9, FLT3m, NPM1m |
| 4Δ | M | 80 | M4 | AML with mutated NPM1 | 198.5 | 25% | 52% | 46,XY | FLT3m, KIT D816V, NPM1m |
| 5 | M | 54 | M1 | AML with NPM1m | 361.5 | 95% | 92% | 46,XY | FLT3m, NPM1m |
| 6 | F | 49 | M4 | AML myelomonocytic | 15.4 | 16% | 63% | 46,XX | FLT3m, NPM1m, CEBPAm |
| 7 | M | 67 | M1 | AML with myelodysplasia | 74.6 | 95% | 84% | complex | − |
| 8*Δ | F | 61 | M5 | AML with myelodysplasia | 82.1 | 77% | 74% | 46,XX,del12p,del20q | − |
| 9 | F | 39 | M5 | AML monoblastic | 37.7 | 65% | 94% | 47,XX,t(3;11),+8 | − |
| 10Δ | F | 49 | M4 | AML with inv16 | 94.2 | 47% | 57% | 46,XX,inv16 | FLT3m |
| 11Δ | M | 58 | M2 | AML with t(8;21) | 100.0 | 60% | 58% | 46,XY,t(8;21) | − |
| 12 | M | 23 | M2 | AML with t(8;21) | 13.7 | 52% | 59% | 45,X,-Y, t(8;21) | − |
| 13 | M | 68 | RAEB-T | AML with myelodysplasia | 3.5 | 0% | 20% | 46,XY | − |
| 14Δ | M | 21 | M1 | AML without maturation | 133.2 | 95% | 88% | 46,XY,add(17p) | − |
| 15*Δ | M | 49 | sec. | AML with myelodysplasia | 89.7 | 85% | n.t. | 46,XY | − |
| 16*Δ | M | 68 | M6a | Acute erythroid leukemia | 6.1 | 93% | 93% | n.t. | − |
| 17* | M | 44 | M4 | AML myelomonocytic | 90.2 | 91% | 92% | complex | − |
| 18 | F | 41 | M4 | AML myelomonocytic | 2.8 | 51% | 72% | 46,XX | − |
| 19 | F | 72 | M4 | Therapy-related AML | 93.2 | 62% | 74% | 46,XX | FLT3m, NPM1m |
| 20 | F | 52 | M1 | AML with mutated NPM1 | 64.1 | 88% | 80% | 46,XX | NPM1m |
| 21*Δ | F | 73 | M1 | AML without maturation | 75.6 | 73% | 84% | 46,XX,t(3;?) | FLT3m |
| 22* | F | 65 | sec. | AML with myelodysplasia | 4.2 | 0% | 19% | 46,XX | FLT3m |
| 23* | M | 70 | sec. | AML with myelodysplasia | 1.9 | 25% | 15% | complex | − |
| 24* | M | 26 | M4 | AML myelomonocytic | 93.9 | 76% | 76% | 46,XY | FLT3m |
| 25* | M | 71 | sec. | AML with myelodysplasia | 13.0 | 77% | 46% | 46,XY | NPM1m, KIT D816V |
| 26 | F | 45 | M4 | AML with myelodysplasia | 66.8 | 53% | 66% | 46,XX | FLT3m |
| 27* | M | 72 | M4 | AML monocytic | 20.3 | 37% | 34% | 46,XY,+11,-16 | FLT3m |
| 28 | M | 40 | M1 | AML with mutated NPM1 | 202.3 | 61% | 65% | 46,XY | NPM1m, FLT3m |
| 29 | M | 75 | sec. | AML with myelodysplasia | 18.8 | 29% | 21% | 47,XY,+mar | JAK2 V617F, FLT3m |
| 30 | F | 50 | M5 | AML with mutated NPM1 | 50.9 | 4% | 23% | 46,XX | NPM1m |
| 31Δ | F | 65 | M4 | AML with myelodysplasia | 62.2 | 79% | 70% | complex | − |
| 32*Δ | F | 54 | M1 | AML without maturation | 23.3 | 81% | n.t. | n.t. | − |
| 33*Δ | M | 59 | sec. | AML with myelodysplasia | 34.3 | 26% | n.t. | 47,XY,add(3),+8 | − |
| 34Δ | F | 84 | M4 | AML myelomonocytic | 132.0 | 8% | 29% | 46,XX | − |
| 35Δ | F | 85 | M1 | AML with myelodysplasia | 1.7 | 0% | 33% | 46,XX,del5q | − |
| 36Δ | M | 64 | M1 | AML with maturation | 53.5 | 94% | 84% | 46,XY | − |
| 37*Δ | M | 53 | M2 | AML with myelodysplasia | 2.8 | 16% | 37% | 45,XY,-7 | − |
*
These patients were analyzed at relapse or persistence of blasts. Abbreviations: WBC, white blood count; F, female; M, male; Yrs, years; FAB, French-American-British cooperative study group; WHO, World Health Organization; PB, peripheral blood; BM, bone marrow; n.t., not tested; FLT3m, mutated FLT3; NPM1m, mutated NPM1; CEBPAm, mutated CEBPA. ΔThese patients were purified for CD34+/CD38− and CD34+/CD38+ subfractions by cell sortin